LLY vs VERU: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. LLY and VERU share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined LLY and VERU exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Eli Lilly (LLY) is one of the world's largest pharmaceutical companies, currently defined by its leadership in the GLP-1 class of medicines for diabetes and obesity. Its tirzepatide molecule is sold as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management, and these products have driven explosive revenue growth amid surging demand for metabolic treatments. Beyond GLP-1s, Lilly has a deep and diversified pipeline and franchises across diabetes, oncology, immunology, and neuroscience, including a closely watched effort in Alzheimer's disease (donanemab, marketed as Kisunla). The company invests heavily in research and in expanding manufacturing capacity to meet incretin demand. Eli Lilly was founded in 1876 and is headquartered in Indianapolis, Indiana. It has become one of the most valuable healthcare companies in the world, with the obesity and diabetes opportunity central to its growth story, balanced by a premium valuation and the eventual prospect of competition and patent expirations.

Full LLY guide

Veru Inc is a small biopharmaceutical company that has repositioned itself around cardiometabolic and obesity disease after earlier chapters in oncology and men's health. Its drug development program now centers on two small molecules: enobosarm and sabizabulin. Enobosarm is the lead asset, an oral selective androgen receptor modulator being developed to preserve lean muscle mass and physical function while enhancing fat and weight loss when used alongside GLP-1 receptor agonists such as semaglutide (Wegovy) and tirzepatide. The strategic logic is that GLP-1 drugs drive large weight loss but also strip away muscle, and a therapy that protects muscle quality could ride alongside one of the fastest-growing drug categories in the world. In September 2025 Veru reported an FDA meeting that clarified the regulatory path, and in March 2026 it enrolled the first patient in its Phase 2b PLATEAU trial of enobosarm plus semaglutide, focused on older, higher-BMI patients.

Full VERU guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• LLY drivers: GLP-1 obesity and diabetes leadership; Manufacturing scale-up.
• VERU drivers: Enobosarm in the GLP-1 muscle-preservation opportunity; Regulatory clarity from the FDA.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: LLY trades at a premium valuation, so any disappointment in obesity-drug growth, pricing, or supply can compress the multiple sharply. For VERU, the dominant risk is clinical and binary: Veru is a small clinical-stage biotech with no approved cardiometabolic product, so a failed, delayed, or ambiguous PLATEAU readout could sharply reduce the value of the entire thesis.

Pick LLY if you believe its drivers more; VERU if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the LLY and VERU guides.

LLY. Eli Lilly trades at a premium pharma multiple that prices in continued rapid growth from the obesity and diabetes franchise plus pipeline optionality. The valuation debate centers on how large, durable, and profitable the incretin market proves to be and how competition (chiefly Novo Nordisk and emerging oral incretins) shapes pricing and share. Figures are approximate and should be verified against the latest filings before drawing conclusions.

VERU. Figures are approximate and tied to the asOf date; verify live numbers before acting. For a clinical-stage biotech like Veru, traditional earnings multiples do not apply because there are no meaningful earnings, so the market prices the probability that enobosarm succeeds against the cash needed to get there. Key dates to watch are the PLATEAU interim DXA data expected in early 2027 and topline data in late 2027, plus any financing that extends the runway but adds shares.

Headline figures (approximate, early 2026): LLY shows revenue (ttm) ~$45 to 55 billion and growing fast (verify), operating margin ~30%+ (verify), gross margin ~80% (typical for branded pharma), p/e (ttm) ~40x to 60x (premium; verify); VERU shows stage Clinical-stage biopharma with no approved cardiometabolic product; results driven by trials, not product revenue, cash position ~$27.6 million cash, cash equivalents, and restricted cash as of March 31, 2026 (up from ~$15.8 million six months earlier), profitability Loss-making; fiscal Q2 2026 net loss narrowed to ~$2.7 million from ~$7.9 million a year earlier, going concern Filings carried a going-concern warning and flagged the need for additional funding.

LLY and VERU are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined LLY and VERU exposure against your real portfolio. It is not an investment adviser.